A parallel group randomised, controlled, multi-centre phase II open label trial to evaluate progression free survival in Cohort A: Pancreatic NETs - peptide receptor radionuclide therapy (PRRT)/capecitabine + temozolomide (CAPTEM) vs. CAPTEM (control) and Cohort B: Midgut NETs - PRRT/CAPTEM vs. PRRT (control).

Trial Profile

A parallel group randomised, controlled, multi-centre phase II open label trial to evaluate progression free survival in Cohort A: Pancreatic NETs - peptide receptor radionuclide therapy (PRRT)/capecitabine + temozolomide (CAPTEM) vs. CAPTEM (control) and Cohort B: Midgut NETs - PRRT/CAPTEM vs. PRRT (control).

Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Dec 2017

At a glance

  • Drugs Octreotate-Lu-177-DOTA-Tyr-3 (Primary) ; Capecitabine; Temozolomide
  • Indications Intestinal cancer; Neuroendocrine tumours; Pancreatic cancer
  • Focus Therapeutic Use
  • Acronyms CONTROL NETS
  • Most Recent Events

    • 20 Nov 2017 Planned number of patients changed from 165 to 72.
    • 10 Jun 2017 Biomarkers information updated
    • 15 Jun 2015 Planned initiation date changed from 1 Feb 2015 to 1 Jul 2015, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top